Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Greg was also central to the planning, design, and construction of this facility
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Further strengthens BaseLaunch's global pharma industry partnerships
Establishing Asymchem’s first manufacturing footprint in Europe
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Subscribe To Our Newsletter & Stay Updated
